Loading...
Loading...
ELEV| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 18.5M |
| Operating I/L | -18.5M |
| Other Income/Expense | -0.5M |
| Interest Income | 0.0M |
| Pretax | -19.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -19.0M |
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company specializing in developing targeted cancer therapeutics. Their lead program, seribantumab, is an anti-HER3 monoclonal antibody currently in Phase II CRESTONE trial for treating advanced solid tumors with neuregulin-1 fusion. The company's focus on genomically defined patient populations sets them apart in the cancer treatment space, allowing for personalized and effective therapies. By leveraging their innovative approach to developing precision medicines, Elevation Oncology aims to generate revenue through the commercialization of their novel cancer treatments.
